Welcome to our dedicated page for MOLECULAR PARTNERS SEC filings (Ticker: MOLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Molecular Partners AG's SEC filings document a foreign private issuer developing DARPin therapeutics for oncology, including targeted radiopharmaceuticals and immune-engaging protein drug candidates. Its Form 6-K reports furnish press releases, annual report materials, clinical and preclinical program updates, financial results, and scientific disclosures tied to candidates such as MP0712, MP0317, MP0533 and other DARPin programs.
The filings also cover shareholder-meeting materials, board elections, compensation votes, consolidated financial statements, and incorporation of certain Form 6-K exhibits into registration statements. Annual report disclosures describe the company's pipeline, partnerships, research and development focus, cash resources, governance framework, and public-company reporting as a Swiss issuer listed on SIX and Nasdaq.
Molecular Partners reports clinical progress for MP0317, announcing dosing of first patients in the investigator‑initiated, randomized Phase 2 TACTIC proof‑of‑concept study in front‑line advanced biliary tract carcinoma (cholangiocarcinoma). The French multicenter trial plans to enroll 75 patients, with 50 in the experimental arm and 25 in the control arm, testing MP0317 plus standard‑of‑care chemoimmunotherapy (durvalumab plus gemcitabine‑cisplatin) versus standard‑of‑care alone. Nine expert trial sites are activated and patient treatment is ongoing.
MP0317 is described as a FAP‑localized CD40 agonist designed to remodel the tumor microenvironment and is hypothesized to improve 12‑month progression‑free survival compared with standard‑of‑care alone. A data update is expected in 2027, with completion of the study in 2028, and a trial‑in‑progress poster has been accepted for presentation at the ESMO Congress 2026 in Madrid. A completed Phase 1 dose‑escalation study in 46 patients with advanced solid tumors across 9 dose levels showed tumor‑localized CD40 activation and tumor microenvironment remodeling, with results published in Nature Cancer.
Molecular Partners AG filed a Form 6-K to share a broad update on its pipeline of targeted alpha Radio-DARPin therapeutics for cancer. The lead candidate MP0712, a DLL3‑targeted Radio-DARPin using Lead‑212, is in a US multicenter Phase 1/2a trial with dosing ongoing in the first cohort.
Initial data from this MP0712 study are expected within the coming months, with a more comprehensive safety and efficacy dataset anticipated in 2027. Separately, a compassionate care early‑access program in South Africa, referred to as MP0714, will use DLL3 Radio‑DARPins with 177Lu/225Ac, underscoring the platform’s isotope‑agnostic design.
The company’s second Radio‑DARPin candidate, MP0726, targets mesothelin and is planned to enter first‑in‑human imaging in H2 2026. Molecular Partners also plans to nominate a new Radio‑DARPin target in H2 2026 and aims to file two INDs across its oncology portfolio in 2027.
Molecular Partners filed a Form 6-K to share news that, together with Orano Med, it has dosed the first patients in a US multicenter Phase 1/2a trial of MP0712, a DLL3-targeting Radio-DARPin carrying a lead-212 (212Pb) payload. This drug candidate is designed for tumors that express DLL3, which is present in over 85% of small cell lung cancer tumors and certain other aggressive neuroendocrine cancers, while remaining low in healthy tissue. The study uses a matched-pair approach: patients first receive 203Pb-labeled MP0712 for imaging and dosimetry, then up to four doses of 212Pb-labeled MP0712 at their assigned dose level. Five US centers are currently recruiting across up to four dose levels. Initial data from this trial are anticipated in the coming months, with a more comprehensive readout on safety and efficacy planned for 2027.
Molecular Partners AG furnished a press release highlighting clinical and scientific progress for its DLL3-targeting Radio-DARPin candidate MP0712. The company is presenting trial-in-progress posters on an ongoing US multicenter Phase 1/2a study in small cell lung cancer and other DLL3-expressing tumors at the 2026 ASCO and SNMMI annual meetings. MP0712, co-developed with Orano Med, is now dosing patients in the first cohort, with objectives focused on safety and defining a recommended Phase 2 dose. Earlier in 2026, initial patient imaging and dosimetry data using a diagnostic 203Pb version showed specific tumor uptake, supporting further development of the therapeutic 212Pb-based MP0712, and the company expects to share initial clinical data from the ongoing study in 2026.
Molecular Partners reported unaudited Q1 2026 results showing continued investment in its oncology pipeline and a smaller loss than a year ago. The company generated no revenue, while research and development expenses were CHF 9.4 million and selling, general and administrative expenses were CHF 4.0 million, leading to an operating loss of CHF 13.4 million and a net loss of CHF 13.1 million (CHF 0.35 per share).
Cash, cash equivalents and short-term time deposits totaled CHF 79 million (approximately USD 100 million) as of March 31, 2026, which is expected to fund operations into late 2027 under current assumptions. During the quarter, a Phase 1/2a study of lead Radio-DARPin MP0712 began enrolling, a Phase 2 study of MP0317 in cholangiocarcinoma started, MP0533 showed ongoing preliminary activity in AML, and preclinical Switch-DARPin candidate MP0632 produced encouraging tumor regression data.
Molecular Partners AG filed a Form 6-K highlighting new Phase 1 results for its tumor-localized CD40 agonist MP0317 and ongoing Phase 2 development. A peer-reviewed paper in Nature Cancer reports that MP0317 activated the CD40 pathway within the tumor microenvironment and showed evidence of tumor microenvironment remodeling in patients with advanced solid tumors.
In the 46-patient Phase 1 monotherapy study, MP0317 demonstrated a favorable safety profile up to the highest tested dose and pharmacokinetics compatible with weekly or every-three-week dosing. One patient achieved an unconfirmed partial response and 14 patients achieved stable disease. An investigator-initiated, randomized Phase 2 trial in front-line cholangiocarcinoma is open with eight sites activated, targeting 75 patients to compare standard-of-care chemotherapy plus durvalumab with or without MP0317.
Molecular Partners AG reported outcomes from its Annual General Meeting, where shareholders elected Clare Fisher to the Board of Directors and approved all Board proposals by a wide majority. Fisher brings more than two decades of healthcare experience, including senior business development and M&A roles at several pharmaceutical and biotech companies.
Shareholders approved the 2025 IFRS consolidated and statutory financial statements, the consultative vote on the compensation report, and the proposal to carry forward the 2025 net loss of CHF 57,853,768, increasing the loss carried forward to CHF 257,293,925. The Board and Management Board were granted discharge for 2025. Steven H. Holtzman did not stand for re-election after 12 years on the Board, while all other directors were re-elected, including Bill Burns as Chairman. KPMG AG was re-elected as statutory auditor for 2026, and Anwaltskanzlei Keller AG as independent proxy until the 2027 AGM. All binding compensation motions for the Board and Management Board were also approved.
Molecular Partners AG has published the invitation to its 2026 Annual General Meeting and proposes Clare Fisher for election to the Board of Directors. The meeting will be held on April 14, 2026, in Schlieren, Switzerland.
Fisher is SVP for Global Business Development and M&A at BeOne Medicines and has over two decades of leadership experience across business development, M&A and strategy in the biotech and pharmaceutical industry. Current Board member Steven H. Holtzman will not stand for re-election after 12 years of service, with the Chair and CEO highlighting his role in key partnerships, listings and COVID drug efforts.
The company also provides a 2026 financial reporting calendar, including an interim management statement for Q1 on May 12, 2026, half-year results on August 25, 2026, and a Q3 interim management statement on October 29, 2026.
Molecular Partners reported full-year 2025 results alongside major advances in its DARPin pipeline. Lead Radio-DARPin MP0712 entered a US Phase 1/2a trial for DLL3-positive small cell lung and other neuroendocrine cancers, with initial clinical data expected in 2026. Second radio program MP0726 targeting mesothelin is moving toward first-in-human imaging, and a new Switch-DARPin immune engager candidate is planned for nomination in H1 2026. MP0317 is in a randomized Phase 2 cholangiocarcinoma study and MP0533 continues in a Phase 1/2a AML trial, with a development update planned in H1 2026.
Financially, the company generated no revenue in 2025 and recorded total operating expenses of CHF 58.1 million, resulting in a net loss of CHF 61.7 million. Cash and short-term time deposits were CHF 93.1 million as of December 31, 2025, which management expects to fund operations into 2028. Operating expenses for 2026 are guided to CHF 45–55 million, and the balance sheet remained debt-free at year-end.
Molecular Partners reports 2025 results showing a deeper net loss alongside disciplined cost control and a solid cash position. Total revenues were CHF 0 million versus CHF 5.0 million in 2024 as a Novartis collaboration wound down, while operating expenses fell to CHF 58.1 million from CHF 66.1 million.
The net loss widened to CHF 61.7 million, or CHF 1.65 per share, compared with CHF 54.0 million in 2024. Cash and short‑term deposits totaled CHF 93.1 million as of December 31, 2025, funding operations into 2028, and headcount decreased to 134 FTE from 158.5.
The company advanced its DARPin pipeline, including the alpha‑emitting Radio‑DARPin MP0712 entering a Phase 1/2a trial, nomination of MP0726, progress on immune cell engagers MP0533 and Switch‑DARPins, and set 2026 operating expense guidance of CHF 45–55 million.